| INTRODUCTION
Globally, in 2012, primary liver cancer was the fifth most common cancer in men and the ninth in women. 1 The alarmingly poor prognosis enhances the burden of primary liver cancer, the second leading cause of cancer mortality in 2012. 1 In high-income countries, an increasing proportion of the most common type of primary liver cancer, hepatocellular carcinoma (HCC), is attributed to hepatitis C virus (HCV) infection.
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Opportunities to increase the uptake of antiviral therapy offer promise for reducing the current and future HCC burden. [2] [3] [4] However, evaluating the success of treatment programmes depends on having solid baseline data and the ability to monitor population-level HCC diagnosis trends, risk factors, and prognosis in different settings over time.
The rising burden of HCV-related HCC can be explained by the natural history of HCV infection, the contribution of risk factors for liver disease progression, such as alcohol-use disorder, and negligible population-level impact of interferon-based treatments on HCV-related liver disease. 5 Given the advent of interferon-free direct-acting antiviral (DAA) therapies, many future cases of HCV-related HCC diagnosis could be prevented if greater numbers of people undergo treatment. 6 Several barriers remain to increase access to HCV treatment programmes, including the high cost of new regimens and treatment capacity in most settings. 7 Further, potential impact of improved therapies on the risk of HCC recurrence and HCC survival is not well understood. 8, 9 As a result, the projected burden of HCC in the DAA era remains unclear, highlighting the need for ongoing international surveillance of HCC to inform and improve public health policy and clinical practice over the next decade.
Globally, British Columbia (BC), Canada; New South Wales (NSW), Australia; and Scotland are among the few settings with established population-based surveillance systems that enable monitoring people with HCV infection by linkage between HCV diagnosis databases and hospitalization records. The aim of this study was to assess trends in population-level HCC diagnosis rates, contribution of risk factors to HCC diagnosis, and survival after HCC diagnosis among people with HCV infection. combination of deterministic and probabilistic linkages of records between the HCV notifications, hospitalization and mortality data sets was undertaken by Information Services Division Scotland.
| MATERIALS AND METHODS

| Data
15
| Study period
Hepatitis C virus notifications were extracted for the study period be- 
| Study outcome
The primary outcome of interest was first-time hospitalization due to HCC. A hospital discharge diagnosis code was used to define HCC diagnosis, coded in either the principal or secondary diagnosis fields of a linked inpatient hospital record (ICD-10 code C22.0). Hereafter, a first-time HCC hospital admission is referred to as HCC diagnosis.
| Exclusion criteria
Exclusion criteria were applied as follows: records where date of birth was missing, and records where the date of HCV notification occurred more than 3 months after date of death (post-mortem notification) or prior to 1 January 1995.
| Statistical analysis
Among people with an HCV notification in each setting, trends in HCC diagnosis numbers were evaluated. Alcohol-use disorder is a standard term used to define continued drinking despite adverse mental and physical consequences. 
| RESULTS
| Study participants
There were 58 487 people with an HCV notification in BC, 84 529
in NSW and 31 924 in Scotland (total n = 174 940). A higher proportion of people from BC (61%) were born during 1945-1964 compared to NSW (41%) and Scotland (24%) ( Table 1) . Across the three settings, 63-65% were male, 29-49% had an HCV notification during 1995-2000, and 18-27% had alcohol-use disorder ( Table 1 ).
The proportion of people with an HCV notification who developed HCC was very similar across the three settings: 1.3% (n = 734) in BC, 1.2% (n = 1045) in NSW and 1.1% (n = 345) in Scotland. Across the three settings, those with an HCC diagnosis were more likely to be born during 1945-1964 and male. Among people with an HCC diagnosis, the proportion of individuals with alcohol-use disorder ranged from 17% in BC, to 23% in NSW and 27% in Scotland (Table 1) .
| Age at HCC diagnosis
The age distribution at HCC diagnosis varied across settings. In BC, NSW and Scotland, those aged 50 years or older at the time of HCC diagnosis comprised 89%, 66% and 77% of the population with an HCC diagnosis in the mid-2000s, respectively. In the early 2010s, people in the same age group comprised 95%, 84% and 87% of the population with an HCC diagnosis in BC, NSW and Scotland, respectively ( Figure 1 ). 
| HCC diagnosis numbers and rates
| Factors associated with HCC diagnosis
In unadjusted analyses across the three settings, HCC diagnosis was associated with older age, male gender and HCV notification year ≥2007. In unadjusted analyses, HBV co-infection was associated with HCC diagnosis in NSW and HIV co-infection was associated with reduced likelihood of HCC diagnosis in BC (Table S1 ). In adjusted analy- Table 2 ). The association between HCC diagnosis and more recent HCV notification years was driven by older age (Table S2 ). CI 0.99, 1.97) ( Table 3) .
| Survival after HCC diagnosis
| DISCUSSION
The burden of HCV-related HCC continued to increase in BC, Canada; NSW, Australia; and Scotland, despite availability of curative interferon-based treatment that had limited uptake and effectiveness. Yet, contrasting reports of HCC occurrence and reoccurrence risk after DAA-induced viral clearance add to current uncertainties on impact of DAA treatments on HCC risk. 8, 9 Older age is a key risk factor for HCC risk among people with cirrhosis, even following SVR; therefore, the apparent higher risk of HCC following SVR in the DAA era is likely due to confounding by older age and also shorter follow-up in DAA era studies. [21] [22] [23] [24] Further evaluation of the issue of HCC risk post-SVR in the DAA era should be possible in the near future in BC, NSW and Scotland, as access to government-funded DAA treatments improve uptake and availability of integrated surveillance data sets to monitor HCC trends.
Other factors influencing HCC outcomes include appropriate HCC screening and timely HCC treatment initiation. The last decade has witnessed developments in the clinical management of HCC 25 ; however, these advances have not been translated into major improvements in HCC outcomes at the population level. HCC screening and diagnosis among people with cirrhosis remain underutilized, given barriers at the patient, provider and system levels, and lack of highquality evidence in favour of screening. 26, 27 In the absence of data from randomized trials, however, observational studies provide evidence linking HCC screening with improved outcomes. 28, 29 Given the rising burden of HCC, this evidence should be used to enhance the patient and provider knowledge of HCC risk factors, screening and treatment options, and improve provision of care through multidisciplinary teams.
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Across the three settings, older age was the strongest predictor of HCC diagnosis. Other factors associated with HCC diagnosis included alcohol-use disorder, male gender and HBV/HCV/HIV co-infection.
These well-documented risk factors for liver disease progression and tumour development could characterize high-risk populations who might benefit from enhanced prevention strategies. 23, 24 Our findings also highlight the implications of the multifactorial aetiology of HCC.
Due to its complex nature and association with advanced liver disease, HCC prevention and management requires close collaboration among a multidisciplinary team of healthcare professionals. 25, [31] [32] [33] Given availability of curative procedures, timely diagnosis, selection of a therapeutic intervention and referral to the appropriate specialist are critical steps for delivery of optimal HCC care.
This study has several limitations. in data access and procurement, and data management. 
